Analyst Ratings February 18, 2026

UBS Lifts Kenvue Price Target to $19 After Q4 Results, Keeps Neutral Rating

Analyst sees quarter as 'better-than-feared' but urges caution as pending Kimberly-Clark deal clouds outlook

By Marcus Reed KVUE
UBS Lifts Kenvue Price Target to $19 After Q4 Results, Keeps Neutral Rating
KVUE

UBS raised its 12-month price target on Kenvue Inc. to $19 from $17 while maintaining a Neutral rating following the company's fourth-quarter results that exceeded expectations. The beat was driven by stronger organic sales, improved margins and a favorable tax rate, but management withheld a 2026 outlook because of the pending acquisition by Kimberly-Clark. UBS highlighted mixed signals in consumption trends and said investor confidence will determine the stock's near-term direction.

Key Points

  • UBS raised its price target on Kenvue to $19 from $17 while maintaining a Neutral rating; the new target sits slightly below InvestingPro's Fair Value with a PEG ratio of 0.7.
  • Kenvue's Q4 beat was driven by stronger organic sales growth, improved gross and operating margins, and a favorable tax rate; gross profit margins were reported at 58.13%.
  • Management withheld a 2026 outlook because of the pending Kimberly-Clark acquisition; the deal and the quarter's mixed results are key items for investors and sectors tied to consumer health and M&A activity.

UBS has increased its price target for Kenvue Inc (NYSE: KVUE) to $19, up from $17, while leaving its rating on the stock at Neutral. The bank's revised target sits marginally below InvestingPro's Fair Value assessment, with Kenvue showing a PEG ratio of 0.7 in that dataset.

The change in forecast follows Kenvue's fourth-quarter performance, which topped analysts' expectations. UBS attributed the outperformance to a combination of stronger-than-anticipated organic sales growth, improvements in gross and operating margins, and a favorable effective tax rate recorded for the quarter.

Kenvue did not provide guidance for 2026, citing its pending transaction with Kimberly-Clark as the reason management withheld a forward-looking outlook. InvestingPro data cited in the report shows Kenvue delivering gross profit margins of 58.13 percent, reinforcing the margin strength noted in the quarterly results.

UBS observed that sentiment among investors ahead of the results had been tilted toward the negative side, primarily because of ongoing softer consumption trends in the United States. In the firm's assessment, the quarter will likely be perceived as better-than-feared in light of the reported metrics.

Analysts at UBS welcomed the return to organic sales growth in the quarter and signaled that international consumption appears to be recovering more favorably than recent U.S. performance. However, UBS cautioned that much of the upside in the quarter was driven by timing-related factors and may not represent a durable inflection in demand.

Looking ahead, UBS emphasized that the direction of the stock depends on whether investors become convinced that Kenvue is on an improved trajectory relative to recent years. The firm suggested many market participants may adopt a wait-and-see stance despite the supportive quarterly report.

For investors focused on income, Kenvue currently offers a dividend yield of 4.51 percent, a level the UBS note said could provide support to the share price while the market gauges future growth prospects. InvestingPro also maintains a detailed research report on Kenvue, listing it among more than 1,400 U.S. equities covered with in-depth analysis.


Additional corporate and market details

In its fourth-quarter and full fiscal year 2025 disclosures, Kenvue reported a 3.2 percent year-over-year increase in sales, outpacing the Street's consensus estimate of 0.4 percent. Despite the top-line growth, adjusted earnings per share for the quarter were $0.27, below analyst expectations of $0.33. Reported revenue for the quarter totaled $3.78 billion, missing the consensus forecast of $4.11 billion even as the company registered sales growth.

The company remains subject to a pending acquisition by Kimberly-Clark. BofA Securities has resumed coverage on Kenvue but did not assign a rating while the takeover remains unresolved, according to the information cited in the note.

On the organic growth composition, Kenvue recorded a modest 1.2 percent increase in organic sales during the quarter. That gain reflected a 2.3 percent benefit from price and mix, which was partly offset by a 1.1 percent decline in volumes.

Market responses from other sell-side firms included Canaccord Genuity raising its price target to $18 from $17 while retaining a Hold rating on the stock. UBS's move to a $19 target and Canaccord's adjustment to $18 underscore analyst attention on both the company's near-term results and the implications of the Kimberly-Clark acquisition.


What to watch

  • Investor reaction to Kenvue's margin improvements and whether those gains can be sustained across upcoming quarters.
  • Progress and any developments related to the pending Kimberly-Clark acquisition that could influence guidance and coverage from brokerages.
  • Trends in U.S. consumption versus international demand, given UBS's view that international consumption appears to be tracking better.

These items reflect the immediate drivers highlighted in the analyst commentary and the company disclosures, and they will likely inform investor positioning in the near term.

Risks

  • Uncertainty created by the pending Kimberly-Clark acquisition - could delay or limit forward guidance and analyst coverage decisions, affecting investor clarity in the healthcare and M&A-sensitive sectors.
  • Signs of softer U.S. consumption that pressured sentiment heading into the quarter - a continued US demand weakness could weigh on revenue and volumes for consumer health companies.
  • Portion of the quarter's upside tied to timing-related factors - if these are not repeated, future quarter-over-quarter improvements in sales and margins may not materialize, impacting consumer staples and retail demand signals.

More from Analyst Ratings

DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026